HER2 overexpression, found in 15–25% of breast cancers (BCs) and 10–30% of gastric cancers (GCs), is a common mechanism to promote cancer progression via the formation of ligand-independent, constitutively active HER2 homodimers [26,27]. The gene discussed is ERBB2; the disease is gastric cancer.